Table 2.
Patient level characteristics n (%)
|
Englesbe 20101 |
John 20132 |
Maruyama 20133 |
||||
| No PVT (n = 3147) | PVT (n = 148) | No PVT (n = 220) | PVT (n = 70) | No PVT (n = 108) | PVT (n = 42) | |
| Sex (M/F) | 1905/1242 | 91/57 | 144/76 | 42/28 | 63/45 | 22/20 |
| Race | ||||||
| Black | 218 (6.9) | 7 (4.7) | - | - | - | - |
| White | - | - | 184 (83.6) | 60 (85.7) | - | - |
| Other | 2545 (80.9) | 131 (88.5) | - | - | ||
| "Nonblack" | "Nonblack" | - | - | |||
| Etiology | ||||||
| AIH | 95 (3) | 8 (5.4) | - | - | - | - |
| Biliary/cholestatic | 173 (5.4) | 7 (5.4) | 24 (11) | 5 (7.1) | - | - |
| Alcohol | 672 (21.4) | 31 (20.9) | 37 (16.9) | 5 (7.1) | - | - |
| Viral | 1253 (39.8) | 50 (34.1) | 62 (28.3) | 16 (27.1) | 108 | 42 |
| Cryptogenic/NASH | 72 (2.3) | 0 | 35 (16) | 12 (17.1) | - | - |
| Other | 449 (14.3) | 22 (14.9) | 37 (16.9) | 20 (28.6) | - | - |
| Age (yr) | 51.5 ± 11.2 | 50.9 ± 10.8 | 55.8 ± 9.1 | 58.4 ± 8.8 | 63.3 ± 8.68 | 62.4 ± 11 |
| MELD | 12.1 ± 7.2 | 13.3 ± 8.3 | 13.8 ± 4.5 | 14.9 ± 5.9 | 10.2 | 10.6 |
1
Presence of PVT at time of initial transplant evaluation or during the pre-transplant period;
2
PVT category includes patients with PVT at baseline (n = 47) and those that developed new PVT during the study period (n = 23);
3
Study only assessed patients with viral hepatitis. No data reported for race. PVT: Portal vein thrombosis; MELD: Model for end stage liver disease; NASH: Non-alcoholic steatohepatitis; M/F: Male/female; AIH: Autoimmune hepatitis.